The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection
Research output: Contribution to journal › Journal article › Research › peer-review
(Val)ganciclovir is used to treat cytomegalovirus (CMV) infection following solid organ (SOT) or hematopoietic stem cell (HSCT) transplantation. Treatment failures occur, but the contribution from 39 known ganciclovir-related mutations (GRMs) in the CMV-UL97 gene remains controversial. We propose a categorization of these GRMs potentially useful when interpreting sequence analyses in clinical settings. The UL97 gene was sequenced from first/recurrent CMV infections among consecutive SOT or HSCT recipients during 2004-2009. GRMs were categorized as: Signature GRM (sGRM) if in vitro ganciclovir IC(50) ratio for mutated versus wild-type virus >2 (n = 24); polymorphic GRM (pGRM) if ratio
| Original language | English |
|---|---|
| Journal | American Journal of Transplantation (Online) |
| Volume | 13 |
| Issue number | 2 |
| Pages (from-to) | 458-66 |
| Number of pages | 9 |
| ISSN | 1600-6143 |
| DOIs | |
| Publication status | Published - Feb 2013 |
- Adult, Cytomegalovirus, Cytomegalovirus Infections, Drug Resistance, Viral, Female, Foscarnet, Ganciclovir, Hematopoietic Stem Cell Transplantation, Humans, Inhibitory Concentration 50, Male, Middle Aged, Mutation, Odds Ratio, Organ Transplantation, Phosphotransferases (Alcohol Group Acceptor), Prevalence, Recurrence, Risk Factors, Time Factors, Treatment Outcome, Young Adult
Research areas
ID: 105597872